CVSIOTCPharmaceutical PreparationsFiscal year ends December 31
CV Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.01−0.00 (-21.13%)
Close on Oct 19, 2026
- Market cap
- $2.30M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0256 (−69.57%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CV Sciences, Inc. saw revenue fall 14.9% to $12.74M over the twelve months to Jun 30, 2026. Free cash flow was -$522.00K.
Revenue
$12.74M
-14.9% vs. a year earlier
Operating income
-$969.00K
TTM Q2 2026
Free cash flow
-$522.00K
TTM Q2 2026
EPS, diluted
$0.00
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.30M
- P/E ratio
- –
- Price to sales
- 0.18
- Price to book
- 1.46
- Dividend yield
- –
- Free cash flow yield
- -22.73%
Fundamentals
- Revenue
- $12.74M
- Net income
- -$2.01M
- EPS, diluted
- $0.00
- Free cash flow
- -$522.00K
- Book value per share
- $0.01
- Diluted shares
- 205M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$12.74M-14.9% YoY
Gross profit
$6.26M-10.0% YoY
Operating income
-$969.00K
Net income
-$2.01M
EPS, diluted
$0.00
Free cash flow
-$522.00K
Reported periodTrailing twelve months